慢性鼻腔金黄色葡萄球菌定植识别新诊断GPA高复发亚组
研究基于两项临床试验的200例新诊断ANCA相关性血管炎患者,每月行鼻腔拭子培养评估慢性鼻腔金黄色葡萄球菌定植(CNSAC)。CNSAC在全部AAV中与复发风险无关,但23/24慢性定植者为GPA,且在广泛型GPA中CNSAC与更高复发率相关(HR=4.10)。预防性T/S未降低复发风险但减少CNSAC。
要点
- 新诊断GPA中CNSAC频率与普通人群相当,占23/151(15.2%)。
- 广泛型GPA中慢性SA定植者复发风险更高(HR=4.10,95%CI 1.37-12.25,P=0.01)。
- 预防性T/S未降低复发风险(OR=0.71,P=0.33),但减少CNSAC(OR=0.19,P=0.04)。
核心结论
- 新诊断GPA中慢性鼻腔SA定植者虽经免疫抑制和预防性T/S治疗,仍具有高复发率,需进一步研究发病机制和治疗。
研究设计与样本
- 两项临床试验共纳入200例新诊断AAV患者,其中早期系统性83例、广泛型117例,每月及复发时行鼻腔拭子培养。
- CNSAC定义为≥75%培养SA阳性,非携带者为所有培养SA阴性,其余为间歇性携带者。
主要发现
- 全部AAV患者中,慢性携带24/200(12%)、间歇性102/200(51%)、非携带74/200(37%)。
- 65例复发患者中,慢性携带者复发10/24(41.7%)、间歇性32/102(31.4%)、非携带23/74(31.1%),P=0.59。
- 全部AAV中CNSAC与复发风险无关(OR=1.57,95%CI 0.66-3.76,P=0.31)。
- 23/24慢性携带者为GPA;广泛型GPA中慢性SA携带者复发率更高(HR=4.10,95%CI 1.37-12.25,P=0.01)。
- 早期系统性GPA免疫抑制期间慢性SA携带者复发率更高(HR=2.73,95%CI 0.95-7.87,P=0.06)。
关键数值与推荐
- CNSAC定义:≥75%的鼻腔培养SA阳性。
- 广泛型GPA慢性SA携带者复发HR=4.10(95%CI 1.37-12.25,P=0.01)。
- 早期系统性GPA免疫抑制期间慢性SA携带者复发HR=2.73(95%CI 0.95-7.87,P=0.06)。
- 预防性T/S与复发风险无关(OR=0.71,95%CI 0.36-1.41,P=0.33),但降低CNSAC(OR=0.19,95%CI 0.04-0.91,P=0.04)。
临床怎么用
- 对新诊断GPA患者可考虑行鼻腔SA培养,识别慢性定植以评估复发风险。
- 慢性鼻腔SA定植的GPA患者即使接受免疫抑制和预防性T/S治疗,仍需警惕高复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV). METHODS: In two clinical trials (n = 200), for early systemic (n = 83) and generalized (n = 117) AAV, nasal swabs were obtained monthly and at the time of a relapse. Chronic nasal SA carriage (CNSAC) was defined as ⩾ 75% of cultures being SA positive, with non-carriers being SA negative in all cultures and remaining patients being intermittent carriers. Fifty-five of 200 (27.5%) patients received prophylactic trimethoprim/sulfamethoxazole (T/S) against Pneumocystis jirovecii . RESULTS: Of the total AAV patients, 24/200 (12%) were chronic, 102/200 (51%) intermittent and 74/200 (37%) non-carriers. Of 65 relapsing patients, 10/24 (41.7%) were chronic, 32/102 (31.4%) intermittent and 23/74 (31.1%) non-carriers (P = 0.59). For all AAV patients, CNSAC was not associated with an increased relapse risk [odds ratio (OR) = 1.57, 95% CI: 0.66, 3.76; P = 0.31]. However, 23/24 chronic carriers had granulomatosis with polyangiitis (GPA). In the 73 patients with generalized GPA (hazard ratio = 4.10, 95% CI: 1.37, 12.25; P = 0.01) and the 78 patients with early systemic GPA during immunosuppression (hazard ratio = 2.73, 95% CI: 0.95, 7.87; P = 0.06), relapse rates were higher for chronic SA carriers. Prophylactic T/S was not associated with a reduced relapse risk (OR = 0.71, 95% CI: 0.36, 1.41; P = 0.33). Nevertheless, prophylactic T/S reduced CNSAC (OR = 0.19, 95% CI: 0.04, 0.91; P = 0.04). CONCLUSION: The frequency of CNSAC in newly diagnosed GPA paralleled that in the general population. This subset of GPA patients (23/151, 15.2%) has a high relapse rate despite immunosuppression and prophylactic T/S treatment, requiring further investigations on pathogenesis and therapy.
引用
- Salmela A, Rasmussen N, Tervaert JWC, et al. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford). 2017. PMID: 28339745. doi:10.1093/rheumatology/kex001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。